The Food and Drug Administration (FDA) has authorized Philip Morris International to market its Zyn nicotine pouches with a modified risk statement. This statement claims that using Zyn instead of cigarettes lowers the risk of several serious diseases, including lung cancer and heart disease. The FDA's decision follows a thorough scientific review concluding the claim is accurate and understandable to consumers. Regulators stated this ensures adult smokers receive clear, science-based information for informed choices. The FDA initially allowed Zyn pouches to be marketed in 2025, citing fewer harmful chemicals compared to cigarettes. An advisory panel previously indicated the proposed statement was likely accurate. However, a tobacco control group opposed the claim, arguing the manufacturer hadn't demonstrated sufficient benefit. The authorization requires ongoing studies to monitor consumer interaction and understanding of the risk information. This approval is valid for five years and can be extended. The FDA reserves the right to withdraw the authorization if the marketing no longer benefits the population, such as if youth uptake significantly increases. Philip Morris International's CEO welcomed the decision, emphasizing the accurate, science-based information now available to adult smokers.